Some but not all observational studies have found that current exposure to abacavir is
associated with increased risk of cardiovascular events such as myocardial infarction, stroke
and cardiovascular death. This study aim to investigate possible adverse effect of abacavir
on platelet reactivity, coagulation and endothelial activation in HIV-1 infected patients.
The study is an open-labeled cross-over trial, where patients receiving antiretroviral
therapy containing abacavir switch treatment to a regimen containing tenofovir and vice versa
for a period of 90 days.